Cipla launches mobile application for asthma screening

07 Jan 2025 Evaluate

Cipla has launched a mobile application designed to enable the first line of screening for asthma in India. According to the Global Burden of Disease report, the total burden of asthma in India is estimated to be around 34.3 million. India has a three-fold higher mortality rate and two-fold higher asthma-associated disability burden compared to the global proportion.

Earlier, the company had obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.


Cipla Share Price

1341.45 12.40 (0.93%)
20-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1724.45
Dr. Reddys Lab 1280.30
Cipla 1341.45
Zydus Lifesciences 901.00
Lupin 2219.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×